Berberine
Natural plant alkaloid with metformin-like metabolic effects, AMPK activation, and gut health benefits.
Evidence Summary
Berberine is among the most-studied botanical metabolic agents, with a large and growing randomized-trial literature. A 2024 systematic review and meta-analysis in Frontiers in Pharmacology (50 RCTs, ~4,150 participants; typical dose 0.9–1.5 g/day for 1–3 months) found berberine alone lowered fasting plasma glucose by about 0.59 mmol/L and 2-hour post-load glucose by about 1.57 mmol/L, and improved lipids (total cholesterol, LDL and triglycerides each down roughly 0.30–0.35 mmol/L); added to standard glucose-lowering drugs it further reduced HbA1c by about 0.69%. A 2025 meta-analysis of placebo-controlled trials in metabolic syndrome reported concordant, statistically significant reductions versus placebo — fasting glucose −0.52 mmol/L, 2-hour glucose −1.61 mmol/L, total cholesterol −0.45 mmol/L, LDL −0.50 mmol/L, triglycerides −0.37 mmol/L, waist circumference −3.3 cm and BMI −0.44 kg/m² — with no significant change in HDL or blood pressure and an adverse-event rate comparable to placebo. LDL and total-cholesterol effects appear strongest with shorter (≤90-day) courses. Trials remain mostly small and heterogeneous, and berberine has a short half-life and meaningful drug-interaction potential (CYP enzymes, P-glycoprotein), so it is best used under clinician guidance with monitoring rather than as a substitute for established therapy. Educational information, not medical advice.
Evidence Scale
Mechanism of Action
Activates AMP-activated protein kinase (AMPK) and inhibits mitochondrial respiratory complex I — mechanisms it shares with metformin — which improves insulin sensitivity and glucose uptake. It also modulates the gut microbiome and bile-acid/GLP-1 signaling, reduces hepatic gluconeogenesis, and upregulates LDL-receptor expression to lower LDL cholesterol.
Who Is This For?
Metabolic syndrome, glucose management, lipid support, AMPK activation. Natural metformin alternative.
Protocol & Dosing
Dose
500mg 2-3x daily with meals. Total 1000-1500mg daily.
Frequency
With meals 2-3x daily
Duration
Ongoing
Protocol Summary
Oral with meals. Divided doses preferred due to short half-life. May combine with other glucose-lowering agents.
Latest Evidence
2024–2025: meta-analyses across 50+ randomized trials
A 2024 systematic review and meta-analysis of 50 randomized trials (about 4,150 participants) found that berberine alone lowered fasting glucose by roughly 0.59 mmol/L and 2-hour post-load glucose by about 1.57 mmol/L, with total cholesterol, LDL and triglycerides each falling roughly 0.30–0.35 mmol/L; when added to standard glucose-lowering drugs it reduced HbA1c by about 0.69%. A 2025 meta-analysis of placebo-controlled trials in metabolic syndrome found concordant, significant reductions versus placebo in fasting glucose, 2-hour glucose, total cholesterol, LDL and triglycerides, plus a roughly 3.3 cm smaller waist circumference — with no significant change in HDL or blood pressure and side effects comparable to placebo.
These are pooled results from mostly small, short (1–3 month) trials with meaningful heterogeneity; they do not establish that berberine prevents disease or replaces established therapy. Berberine has a short half-life and can interact with medications metabolized by CYP enzymes or P-glycoprotein, and it is not recommended in pregnancy or breastfeeding. Use under qualified clinician supervision with biomarker monitoring. Educational information, not medical advice.
Placebo-controlled meta-analysis · 2025
Berberine vs placebo: pooled effect on metabolic markers
Pooled mean differences vs placebo, 95% CI. Source: Frontiers in Pharmacology (2025), meta-analysis of placebo-controlled RCTs of berberine in metabolic syndrome.
Related on Peak Human
Berberine (Supplement)
The paired supplement monograph: forms, dosing and quality.
Metformin
Berberine shares AMPK activation and complex-I inhibition with metformin.
Diabetes & Metabolic Health
Berberine is studied as an adjunct for glucose control.
Optimization Service
Biomarker-tracked metabolic optimization at Peak Human.
Diagnostic Testing
Measure fasting glucose, HbA1c and a lipid panel before and during.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Berberine for type 2 diabetes: meta-analysis of 50 RCTs — Front. Pharmacol. (2024) · Berberine on components of metabolic syndrome: placebo-controlled meta-analysis — Front. Pharmacol. (2025) · Berberine alone or in combination in T2DM: systematic review & meta-analysis (2024)
Interactions & Precautions
Contraindications
- Pregnancy
- Drug interactions (CYP enzymes)
Potential Risks
- •Drug interactions
- •GI effects
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Divided dosing (with meals) offsets berberine's short half-life; dihydroberberine may improve absorption. GI effects (cramping, constipation) are common early and usually settle. Screen for CYP3A4/CYP2D6 and P-glycoprotein drug interactions (e.g., statins, cyclosporine, some anticoagulants). Monitor fasting glucose, HbA1c and a lipid panel; watch for additive hypoglycemia when combined with other glucose-lowering agents. Avoid in pregnancy and breastfeeding.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation